Evidence map›Paper›PMID 34249456›Full record

ArticleAmerican journal of cancer research2021

Ewing sarcoma outcomes in a country with limited resources: Egypt as an example.

Ahmed Mohammed Morsy, Salah Abdel-Hadi, Khalid Mohammed Rezk, Gamal Amira, Badawy Mohammed Ahmed, Marwa Tammam Hussien, Mahmoud Gamal Ameen, Hosam Eldein Mostafa Kamel, Doaa Mohamed Fouad, Alia Mohamed Attia and 14 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 2 institutions in 1 country.

Ahmed Mohammed MorsyPediatric Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Salah Abdel-HadiPediatric Oncology, National Cancer Institute, Cairo University Cairo, Egypt.
Khalid Mohammed RezkSurgical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Gamal AmiraSurgical Oncology, National Cancer Institute, Cairo University Cairo, Egypt.
Badawy Mohammed AhmedSurgical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Marwa Tammam HussienPathology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Mahmoud Gamal AmeenPathology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Hosam Eldein Mostafa KamelRadiology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Doaa Mohamed FouadRadiology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Alia Mohamed AttiaRadiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Asmaa SalahRadiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Osama Mostafa Abd ElbadeeRadiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Ayatallah Ali YousseifRadiotherapy and Nuclear Medicine, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Marwa Ismail AbdelgawadClinical Oncology and Nuclear Medicine, Faculty of Medicine, Assiut University Assiut, Egypt.
Asmaa Hussein FathyClinical Oncology and Nuclear Medicine, Faculty of Medicine, Sohag University Sohag, Egypt.
Yasmine Nagy ElwanyCancer Management and Research, Medical Research Institute, Alexandria University Alexandria, Egypt.
Islam Karam-Allah RamadanOrthopedic Surgery and Traumatology, Faculty of Medicine, Assiut University Assiut, Egypt.
Khaled Hassan MosallamOrthopedic Surgery, Hand & Reconstructive Microsurgery, Faculty of Medicine, South Valley University Qena, Egypt.
Ahmed Ibrahim Abd ElwahabCardio-Thoracic Surgery, Faculty of Medicine, Assiut University Assiut, Egypt.
Khaled Hashim MahmoudPediatrics, Faculty of Medicine, Assiut University Assiut, Egypt.
Maged Abdel Fattah AmineMedical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Ahmed Refaat Abd ElzaherMedical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Hanan Ahmed EltybMedical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Ahmed Mubarak HefniMedical Oncology, South Egypt Cancer Institute, Assiut University Assiut, Egypt.
Assiut University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As the scarcity of published research that comprehensively and meticulously analyzed the patient, disease, and treatment factors of prognostic significance in Ewing sarcoma (EWS) in Egypt; This study aimed at assessing survival outcomes of EWS in Upper Egypt, delineating factors of prognostic significance in comparison to other leading oncology centers in Egypt and internationally. By retrospectively reviewing medical records of 85 patients with a verified diagnosis of EWS in the period from 2001 to 2015 at Pediatric and Medical Oncology Departments at South Egypt Cancer Institute; We gathered data relevant to the patient, disease, and treatment variables of the study. Survival was estimated using the Kaplan Meier method and differences between various groups were determined by log rank test. Univariable and multivariable analyses were performed using Cox regression. With a median follow-up period of 62.7 months (95% CI 52.2-73.2, SE=5.4) for the study patients, the estimates of event-free survival (EFS) and overall survival (OS) at 3 and 5 years were 42.1% and 50.6%, and 40.8% and 48.5%, respectively. Metastatic disease at initial presentation (HR=8.91, 95% CI, 4.00-19.9; P<0.0001) stood as the most powerful predictor of OS in the multivariable analysis, followed by surgery used as a local modality (HR=0.16, 95% CI, 0.06-0.44; P=0.0004). Response to neoadjuvant chemotherapy (HR=2.61, 95% CI, 1.11-6.13; P=0.028), primary tumor size (HR=2.49, 95% CI, 1.03-6.03; P=0.044) were also shown to be significantly associated with OS. Radiotherapy as a local modality, whose effect, apparently shown to increase the hazard of events occurrence in the univariable analysis, an effect that was reversed to reveal EFS advantage (HR=0.41, 95% CI, 0.18-0.95; P=0.036) after control of other variables. With 5-year OS of 48.5%, our survival results were comparable to those previously published from Egypt; however, differences still exist between centers due to varied representative study samples. However, outcomes in Egypt in general are still inferior to internationally published studies.

Indexed as

bone neoplasmsEwing sarcomaEwing sarcoma family of tumorsprimitive neuroectodermal tumorsoft tissue neoplasmsWHO classification of tumors

Identifiers

PMID34249456
PMCPMC8263650
OpenAlexW3179128438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.